cas 866460-33-5

  • Wuhan HHD Setipiprant CAS 866460-33-5 Hair Loss Treatment

    Setipiprant (INN) (developmental code names ACT-129,968, KYTH-105) is a drug originally developed by Actelionwhich acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). Setipiprant was initially researched as a treatment for allergies and inflammatory disorders, particularly asthma, but despite being well tolerated in clinical trials and showing reasonable efficacy against allergen-induced airway responses in asthmatic patients,Setipiprant failed to show sufficient advantages over existing drugs and was discontinued from further development in this application.

    Email Details
Get the latest price? We'll respond as soon as possible(within 12 hours)

Privacy policy